Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety
Journal of Hepatocellular Carcinoma · 2026-04 · Volume 13 · 1-18
DOI: 10.2147/jhc.s582999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-04. Verfasst von Lin Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
- Department of Interventional Hepatology, The Fifth People's Hospital of Ganzhou, Ganzhou, Jiangxi, People's Republic of China.
- Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China.
- Department of Pathology, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Zitieren
APA
Xu, L., Wang, X., Lai, X., Li, A., Mao, Y., Wang, X., & Wu, J. (2026). Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety. Journal of Hepatocellular Carcinoma, Volume 13, 1-18. https://doi.org/10.2147/jhc.s582999
Vancouver
Xu L, Wang X, Lai X, Li A, Mao Y, Wang X, et al. Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-18. doi:10.2147/jhc.s582999
BibTeX
@article{Xu2026,
author = {Xu, Lin and Wang, Xiao and Lai, Xiaohuan and Li, An and Mao, Ye and Wang, Xu and Wu, Jianbing},
title = {Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--18},
doi = {10.2147/jhc.s582999}
}
EUVIMED